Structure
Silmitasertib sodium salt, Inhibitor
Silmitasertib sodium salt
Purity
99.49%
Synonyms
Silmitasertib sodium salt; CX-4945 sodium salt; inhibitor
Purity/Purification
99.49%
Form/Format
Solid. Powder
Solubility
H2O: 16.67mg/mL (44.84mM) Need ultrasonic
DMSO: 6mg/mL (16.13mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
DMSO: 6mg/mL (16.13mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C19H11ClN3NaO2
SMILES
[Na+].[O-]C(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21
CAS Number
1309357-15-0
Target & IC50
CK2alpha: ic50
CK2alpha': ic50
CK2
Autophagy
CK2alpha': ic50
CK2
Autophagy
In Vitro
Silmitasertib (CX-4945) (25 or 75mg/kg, p.o.) is well tolerated. It showed robust antitumor activity with concomitant reductions of the mechanism-based biomarker phospho-p21 (T145) in murine xenograft models[1].
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
-80 degree C for 2 years in solvent
Structure
Structure
Related Product Information for Silmitasertib sodium salt, inhibitor
Silmitasertib sodium salt is a potent and orally bioavailable, highly selective inhibitor of CK2(IC50 of 1nM, CK2alpha).
Product Categories/Family for Silmitasertib sodium salt, inhibitor
References
Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98.
Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98.
Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of beta-catenin. Oncotarget. 2016 Aug 16;7(33):53191-53203.
Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of beta-catenin. Oncotarget. 2016 Aug 16;7(33):53191-53203.
Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-kappaB. Oncotarget. 2016 Jan 12;7(2):1323-40.
Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-kappaB. Oncotarget. 2016 Jan 12;7(2):1323-40.
Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment,of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.
Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment,of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.
Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98.
Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of beta-catenin. Oncotarget. 2016 Aug 16;7(33):53191-53203.
Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of beta-catenin. Oncotarget. 2016 Aug 16;7(33):53191-53203.
Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-kappaB. Oncotarget. 2016 Jan 12;7(2):1323-40.
Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-kappaB. Oncotarget. 2016 Jan 12;7(2):1323-40.
Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment,of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.
Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment,of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.
Similar Products
Product Notes
The Silmitasertib sodium salt (Catalog #AAA5754751) is an Inhibitor and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "Silmitasertib sodium salt, Inhibitor" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
